Vaccitech, startup behind Oxford COVID-19 vaccine tech, falls 20% in Nasdaq debut

(Reuters) -American depositary shares of Vaccitech fell nearly 20% in their Nasdaq debut on Friday, giving the co-inventor of the COVID-19 vaccine developed by AstraZeneca Plc and Oxford University a market value of about $464 million.
The biotech firm's shares opened at $13.62, below the initial public offering (IPO) price of $17 apiece for 6.5 million of its American depositary shares.
The UK-based company was started by two Oxford University scientists and spun out of the university's Jenner Institute in 2016. Its co-founder Sarah Gilbert was among the scientists who led AstraZeneca's COVID-19 vaccine development efforts.
Vaccitech said it planned to use the proceeds from the IPO to fund the development of its COVID-19 vaccine technology for treatments targeting prostate cancer, hepatitis B HPV and non-small cell lung cancer.
The company's vaccine ...


Read More on Datafloq

Comments

Popular posts from this blog

Underwater Autonomous Vehicles Helping Navy Get More for the Money 

Canada regulator seeks information from public on Rogers-Shaw deal